Kinase Inhibition as Treatment for Acute and Chronic Graft-Versus-Host Disease
Allogeneic hematopoietic stem cell transplantation (allo-HCT) is a potentially curative therapy for patients suffering from hematological malignancies via the donor immune system driven graft-versus-leukemia effect. However, the therapy is mainly limited by severe acute and chronic graft-versus-host...
Saved in:
Main Authors: | Lukas M. Braun, Robert Zeiser |
---|---|
Format: | article |
Language: | EN |
Published: |
Frontiers Media S.A.
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/8e05d6cf6e4145bcafbadad76c11be1c |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Ibrutinib protects T cells in patients with CLL from proliferation-induced senescence
by: Joanne E. Davis, et al.
Published: (2021) -
Immune Dysregulation and Infectious Complications in MPN Patients Treated With JAK Inhibitors
by: Daniele Cattaneo, et al.
Published: (2021) -
The Russian Expert Council on the application of new highly selective inhibitor of Bruton’s tyrosine kinase zanubrutinib in the treatment of patients with relapsed/refractory mantle cell lymphoma. Event review
by: Kamil D. Kaplanov
Published: (2021) -
Bruton’s Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia
by: Leigh Naylor-Adamson, et al.
Published: (2021) -
ELEVATE-RR – first head-to-head trial of acalabrutinib versus ibrutinib in previously treated high risk chronic lymphocytic leukemia
by: Tatiana E. Bialik, et al.
Published: (2021)